| Autor: |
Djebbari, Faouzi, Hubenov, Huben, Neelakantan, Pratap, Wolf, Julia, Offer, Mark, Khera, Akhil, Louka, Eleni, Vallance, Grant, Kothari, Jaimal, Moore, Sally, Ramasamy, Karthik |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Feb2020, Vol. 188 Issue 4, pe57-e60, 4p, 2 Charts |
| Abstrakt: |
Twenty-nine patients (97%) received at least two cycles of therapy and one patient discontinued carfilzomib after one cycle. Carfilzomib therapy is ongoing in 17 patients and was discontinued in 13 patients. Five patients received full twice-weekly dosing throughout therapy, and six patients were dose-reduced to weekly upfront (i.e. from cycle 1). Depending on the severity of hypertension, management consisted of introducing an antihypertensive (e.g., amlodipine) in two patients, an antihypertensive dose increase in two patients, carfilzomib dose reduction in two patients, and an antihypertensive plus carfilzomib dose reduction in one patient. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text